Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
Research Swells in Myelofibrosis With JAK Inhibitors, Novel Agents
May 13th 2020Prithviraj Bose, MD, discusses the current role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and the novel agents that are being explored as single agents and in combination with ruxolitinib.
Read More
Long-Term Data Show Nivolumab/Ipilimumab as Preferred Frontline Regimen in RCC
April 30th 2020Nizar M. Tannir, MD, FACP, discusses the 42-month follow-up results from the CheckMate-214 trial in advanced renal cell carcinoma and provides perspective on other approved combinations in the frontline setting.
Read More
Imaging Plus Elastography Enhances Surgical Margin Assessment in Breast Cancer
April 30th 2020Quantitative microelastography demonstrated increased sensitivity, specificity, and accuracy in detecting positive surgical margins in combination with optimal coherence tomography versus optimal coherence tomography alone in women who received breast-conserving surgery.
Read More
PSMA-Targeted Radionuclide Therapy Shows Preliminary Activity in mCRPC
April 10th 2020Scott T. Tagawa, MD, MS, discusses the results of the phase I dose-escalation trial, the advantages of using an alpha emitter and a monoclonal antibody, and the possibility of combining the modality with other classes of agents in prostate cancer.
Read More
Acalabrutinib Triplet Impresses in Frontline CLL, Advances to Phase III Study
April 7th 2020The addition of acalabrutinib (Calquence) to venetoclax (Venclexta) and obinutuzumab (Gazyva) was shown to be highly active in patients with newly diagnosed chronic lymphocytic leukemia, eliciting deep and durable responses.
Read More
Immune Correlates May Indicate Responsiveness to Ipilimumab in mCRPC
April 3rd 2020A subset of patients with metastatic castration-resistant prostate cancer who have low tumor mutational burden may benefit from checkpoint inhibition with ipilimumab if the tumor has a high density of CD8-positive T cells and increased interferon-interferon gamma signaling.
Read More